Pfizer Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Morning, everyone. Day two of our Jefferies London Healthcare Conference. It's been really great to see everyone in the attendance. My name's Akash Tewari, for those who don't know me. I head our biotech and research efforts internally within the firm. I have the pleasure of hosting Albert, CEO of Pfizer, one of the more impactful leaders when it comes to understanding what's going on with U.S. healthcare, and that's going to be something we'll talk about. Albert, why don't I hand it off to you for some intro remarks, and we'll get started.
Thank you. It's a great pleasure to be here. Pfizer had entered the LOE period, which was highly anticipated, and it's expected to last another two years. This is a period for which we were preparing for a long time. After the COVID success, we invested more than anyone else. Actually, we invested $80 billion in acquisitions that will help us overcome through new launches and through building pipeline, because many of the acquisitions were platforms, to be able to overcome the headwinds of the LOE period. Actually, $80 billion, to give you a magnitude, is largest, and the second one is around $40 billion in the post-COVID period. It's significant, more than anybody else. In addition to that, we control our costs, and we build our pipeline. I think the first data are showing that the strategy works well.
Our launch products, they are growing at 32% this quarter, and it's accelerating actually the growth rather than decelerating. They are already amounting to a rounding of $15 billion-$16 billion annualized revenues, and going. The pipeline, it is progressing very nice. 20 phase III studies started this year alone, almost double than year before, right? It's a significant also acceleration of building the pipeline. We, in the last 11 quarters, we were able to beat analyst expectations 11 times out of 11 in EPS and 10 times out of 11 in revenue. It's high quality. It's a company that knows what it wants to achieve. We have a plan, and we are executing it very well. I'm very optimistic that we will exit the LOE period, as we said, with a high single-digit growth in the next five years.
Right. Maybe to that point, you've talked about 2028 being the end of kind of that LOE period, and then the high single-digit growth going from there. When you look at street estimates, because I feel like to your point, you've been telling everyone, "Let's not focus on the next couple years. Let's think about the kind of 2030 plus story on Pfizer." Where has your team gotten more confident on the pipeline side over the last couple years? What do you think we're missing about the 2030 plus story on Pfizer that you have a ton of confidence on right now?
Yeah. I will say that our revenue streams is four categories. The LOE products, I think there is no big discrepancy because it's easy to predict. There are analogs that know how the products will perform. Then there is all the in-line portfolio, the products that they have long history of selling. Over there also, there is not much discrepancy with the Street, because you can predict them quite well. Where there is discrepancy in the Street are in two categories. Pipeline, you mentioned, it's only one of them. One is the new launches, and that are coming now. In all of these products, I can go one after the other. ELREXFIO, it's a new launch, huge disconnect between us and the Street. The Street has us at $600 million and has the competing product at $5 billion. There is something wrong with that. What are the assumptions? Because we are aspiring to have a profile with same efficacy and maybe better tolerability.
So, I would challenge that. NURTEC, the Street has us at $2.5 billion, which is another new launch product. We are already at two. So it's and going. I can go on and on in new launches that there is significant behind what they should be. Then on the pipeline, again, the obesity portfolio, very big disconnect. The CDK4, very big disconnect. PD1, VEGF, very big disconnect. So over there, I think the disconnect is either because some of you, they don't even model them.
Some of you that are very conservative. As pipeline will start having readouts, I think we will be able to close the gap and come to the real number.
Understood. I definitely want to talk about the pipeline, but I also want to hit on, to your team's credit, you guys have had $7.2 billion in net savings so far. You've got an OPEX of around $25 billion, and there is this. When I talk to you, and especially when you talk about AI and efficiencies, and I remember you were in our conference in June, you said, "My single biggest priority is implementing AI and really in every part of our organization." Should we really think about this $7.2 billion as, okay, well, this is what Pfizer's done, and this is the cost cut, and we're done? I look at the way you think about efficiency gains with AI, and then also just efficiency gains within the company as this kind of like ongoing process.
You might actually have even more operating leverage than people realize. Talk to me about operating efficiencies, whether it is through AI or else, as we go out into the end of the decade, where you feel like maybe we are not understanding what is going on on the ground level.
The $7.2 billion is real. It is going to be materialized by this year, which is ending in a month or so. So, it is a testament to us that we were able to do it over a few years without affecting the top line. Actually, the top line is doing much better than anybody else would expect. We already announced an additional $1.5 billion. You are right that with AI, I do not think that there is limitation as to what I will tell you how I see the world. I see the world that right now, we are having China growing their biotech business and having ambition to become global players. I think they will be successful.
I think by year 2030, they will represent my major competition. It is not going to be AstraZeneca or Lilly. It is going to be, I think, Chinese companies. They come and they introduce a different league.
Us, Lilly, AstraZeneca, one is better in sales, one in marketing, one in R&D, but we are pretty much one category. They are coming half the cost.
three, four times the speed. If we want to compete with them by year 2030, we need to be half the cost, three, four times the speed. That sounds very difficult to achieve, unless if AI delivers on the promise. AI, for me, is the biggest lever to be able to build the Pfizer of the future, but I repeat needs to be productive at three, four times the speed and half the cost.
Understood. It was interesting, and look, it is always a sad announcement when people get laid off, there is no doubt. But I saw with AstraZeneca, I think they recently laid off, I think it was 600 people. It was $120 million in cost. I do think that kind of stuck out to us when we think about SG&A and really how costly it can end up being. We have talked about speed, and that will be a process, but when we think about where AI could have the biggest efficiency gain, I noticed that every pharma basically beat on SG&A in Q3, and we are not looking at the transformation that maybe is happening right now.
When you think about AI allowing your sales force to target the right patient more productively, do more with less, do you feel like that is actually where the first impact on the P&L will be with AI, is sales force efficiency adoptions?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
